Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns - Featured image
Women's Cardiovascular Health

Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns

Without improved prevention, cardiovascular disease rates in U.S. women could climb from 10.7% in 2020 to 14.4% in 2050, warns the American Heart Association. Rising obesity, diabetes, and high blood pressure are key drivers, especially among younger women and underserved groups. Experts call for urgent action on early detection and lifestyle changes.

Shotlee·February 25, 2026·Updated Feb 25, 2026·7 min read
Share:

Contents

  1. 01Understanding Cardiovascular Disease in Women
  2. 02The AHA's Projection Methodology
  3. 03Trends Across Age Groups and Demographics
  4. 04The Potential Role of GLP-1 Medications
  5. 05Prevention and Early Detection Strategies
  6. 06Key Takeaways: What This Means for Patients
  7. 07Conclusion
  8. 08Key Projections for Adult Women
  9. 09Why Disparities Matter
  10. 10Practical Steps for Women

Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns

A groundbreaking forecast from the American Heart Association (AHA) reveals that heart disease and stroke in women are set to surge significantly over the next 25 years. Without better prevention and early detection, the number of women living with cardiovascular disease will increase substantially in the coming decades, the AHA said Wednesday. Using historical trends from two national health surveys and census estimates of population growth, the heart association forecast that the percentage of women with at least one type of cardiovascular disease will climb by more than a third, from 10.7% in 2020 to 14.4% in 2050.

Cardiovascular disease is already the leading cause of death for women in the U.S. This projection underscores the urgent need for targeted interventions, particularly as risk factors like obesity, diabetes, and high blood pressure continue to escalate.

Understanding Cardiovascular Disease in Women

The most common form of cardiovascular disease is coronary heart disease, which occurs when fatty deposits called plaque build up in the heart's arteries, preventing them from delivering oxygen-rich blood to the heart muscle. Other types included in the new report are heart failure, when the heart struggles to fill with and pump blood; atrial fibrillation, a type of abnormal heart rhythm; and stroke. These conditions not only reduce quality of life but also impose significant burdens on healthcare systems and families.

Women often experience heart disease differently than men. Symptoms can be subtler, such as fatigue, nausea, or jaw pain rather than classic chest pain, leading to delayed diagnosis and worse outcomes. Early recognition is crucial, especially as projections show increases across all age groups.

The AHA's Projection Methodology

The scientific statement's findings are "a call to action," said Dr. Stacey Rosen, volunteer president of the American Heart Association and executive director of the Katz Institute for Women's Health at Northwell Health in New York City. Each year, the association produces scientific statements and guidelines based on expert consensus to promote longer, healthier lives.

The statement's authors looked at several years' worth of data from two national surveys. One was the National Health and Nutrition Examination Survey, from 2015 to 2020, which asks adults and children about their health and diet. The other was the 2015-to-2019 Medical Expenditure Panel Survey, an annual government survey that asks a large sample of people and families, their medical providers and employers about the cost and use of health care and health insurance coverage. The authors used census forecasts for population growth to extend those historical trends into the future.

Key Projections for Adult Women

  • Prevalence of cardiovascular disease: from 10.7% in 2020 to 14.4% in 2050.
  • High blood pressure: from 48.6% to 59.1%.
  • Diabetes rates: from 14.9% to 25.3%.
  • Obesity: from 43.9% to 61.2%.

The aging of the population is partly driving the increases, said Dr. Karen Joynt Maddox, a cardiologist, chair of the group that wrote the paper. Joynt Maddox is professor of medicine and public health at the Washington University School of Medicine in St. Louis. Rising rates of diabetes, obesity, and high blood pressure are also factors, all of which together and independently raise the risk for heart conditions.

Trends Across Age Groups and Demographics

Those cardiovascular risk factors are increasing across all age groups, including young women ages 20 to 40. The rate of obesity is also projected to rise among girls, from 19.6% to 32.0%. "That's setting up an entire generation of girls and young women to develop these cardiovascular diseases at a much younger age," Joynt Maddox said.

Based on questions in one of the surveys, the percentage of women who eat poorly or don't get enough exercise is expected to decline slightly, and smoking will continue to drop. However, the share of women with sleep problems will rise. Most of the adverse trends are expected to be more pronounced among girls and women who identify as Black, Hispanic, Indigenous, or multiracial.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Why Disparities Matter

Structural inequities, including access to healthcare, nutritious foods, and safe exercise spaces, exacerbate these trends in underserved communities. Addressing them requires policy changes alongside individual efforts.

The Potential Role of GLP-1 Medications

The study didn't take into account the growing use of GLP-1 drugs, the powerful weight-loss and Type 2 diabetes medications. Research has also shown that the drugs can help lower the risk of recurring heart attacks and recurring episodes of heart failure, Rosen said. Their impact 30 years from now on cardiovascular diseases and its risk factors, like obesity and diabetes, is uncertain, Rosen said, adding that "the long-term safety is something that has to continue to be studied."

Research has also shown that many people stop using the drugs because of unpleasant side effects and then regain much of the weight they lost. There are other hurdles to the weight-loss medications. "Not all communities can afford the out-of-pocket expenses for GLP-1s, and unfortunately, we may see a widening of disparities in cardiovascular risk factors and outcomes," said Norrina Bai Allen, an epidemiologist specializing in cardiovascular disease who is director of the Institute for Public Health and Medicine at Northwestern University's Feinberg School of Medicine.

GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), mimic gut hormones to reduce appetite, slow gastric emptying, and improve insulin sensitivity. While promising for metabolic health, patients should discuss eligibility with providers, monitoring for gastrointestinal side effects like nausea or more serious risks like pancreatitis.

Prevention and Early Detection Strategies

There have been major advances in lifesaving treatments for heart disease. But this is an opportunity to rethink how to improve prevention and early detection, Rosen said. In the meantime, women can work now to lower their lifetime risk of developing heart problems, Joynt Maddox said.

Getting regular checkups, taking prescribed medications, and building healthy habits around diet and exercise are key, she said, especially around pregnancy, when diabetes and high blood pressure may first appear, and during menopause, when cholesterol, blood pressure, and sleep change. It's never too late or too early to begin. "Eighty percent of each of our risks for heart disease is preventable, and it starts with awareness," Rosen said.

Practical Steps for Women

  • Monitor Blood Pressure and Blood Sugar: Annual screenings, especially post-pregnancy or during menopause.
  • Adopt a Heart-Healthy Diet: Emphasize fruits, vegetables, whole grains, and lean proteins; limit processed foods and sugars.
  • Exercise Regularly: Aim for 150 minutes of moderate activity weekly.
  • Prioritize Sleep and Stress Management: 7-9 hours nightly; practices like meditation.
  • Track Symptoms: Use apps like Shotlee to log blood pressure, weight, and side effects from medications for better doctor discussions.

For those with obesity or diabetes, consult about GLP-1 therapies, weighing benefits against costs and side effects.

Key Takeaways: What This Means for Patients

  • The AHA projects a 34% rise in women's CVD prevalence by 2050, fueled by aging, obesity (to 61.2%), diabetes (to 25.3%), and hypertension (to 59.1%).
  • Younger women and marginalized groups face heightened risks.
  • GLP-1 drugs offer potential but with uncertainties in long-term use and access.
  • 80% of heart disease risk is preventable through lifestyle, screenings, and awareness.

Conclusion

The AHA's warning on rising heart disease in women is a pivotal moment for action. By focusing on modifiable risk factors, equitable access to care, and emerging therapies like GLP-1 medications, we can alter this trajectory. Women: Schedule your checkup today, track your health metrics, and empower yourself with knowledge to safeguard your heart for decades ahead.

Original source: TODAY.com

View original article →
#heart disease women projection 2050#AHA cardiovascular disease forecast women#obesity diabetes rise women heart risk#GLP-1 drugs cardiovascular benefits women#high blood pressure women prevalence 2050#women's heart disease prevention strategies#cardiovascular disparities Black Hispanic women#young women obesity heart disease risk
  1. Home
  2. Blog
  3. Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community